Massidda B, Mascia V, Broccia G, Pasqualucci S, Deplano W, Desogus A, Luxi G, Pellegrini A
Minerva Med. 1977 Feb 21;68(4):235-41.
2-alpha-methyl-17-beta hydroxy-androstan-3-one was given to advanced breast cancer patients whose general condition (preterminal in many cases) or haematological picture precluded other cytostatic management. Rapid progression of the tumour was noted in 65%, improvement in 15% and no change in 20%. It is felt that androgens alone should only be given where other more effective treatments are contraindicated. They can be associated with polychemotherapeutic courses to exploit their anabolising and antianaemic activity.
将2-α-甲基-17-β-羟基雄甾-3-酮给予晚期乳腺癌患者，这些患者的一般状况（在许多情况下为终末期）或血液学情况使其他细胞毒性治疗方法不适用。65%的患者肿瘤进展迅速，15%的患者病情改善，20%的患者病情无变化。有人认为，仅在其他更有效治疗方法禁忌时才应使用雄激素。它们可与多药化疗疗程联合使用，以发挥其合成代谢和抗贫血活性。
